2015
Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility
Sigmon SC, Meyer A, Hruska B, Ochalek T, Rose G, Badger GJ, Brooklyn JR, Heil SH, Higgins ST, Moore BA, Schwartz RP. Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility. Addictive Behaviors 2015, 51: 136-142. PMID: 26256469, PMCID: PMC4558243, DOI: 10.1016/j.addbeh.2015.07.030.Peer-Reviewed Original ResearchConceptsInterim buprenorphine treatmentBuprenorphine treatmentWeek 2ASI drug composite scoresIllicit opioid abstinenceOpioid-dependent adultsIllicit opioid useDrug composite scoresPercent of participantsInitial feasibilityPast-month drug useWaitlist delaysOpioid cravingOpioid withdrawalBuprenorphine administrationOpioid useSecondary outcomesBuprenorphine inductionDaily medicationOpioid abstinencePrimary outcomeIllicit opioidsOpioid dependenceWeek 12Agonist maintenance
2014
Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence: A Randomized Clinical Trial
Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor P. Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence: A Randomized Clinical Trial. JAMA Internal Medicine 2014, 174: 1947-1954. PMID: 25330017, PMCID: PMC6167926, DOI: 10.1001/jamainternmed.2014.5302.Peer-Reviewed Original ResearchConceptsPrescription opioid dependenceOngoing maintenance therapyIllicit opioid useMaintenance therapyOpioid dependenceBuprenorphine taperBuprenorphine therapyTaper groupMaintenance groupOpioid usePrimary careClinical trialsPrimary care-based treatmentSignificant public health burdenBuprenorphine maintenance therapyOngoing maintenance treatmentPrimary care physiciansEvidence-based guidelinesPrimary care sitesPublic health burdenWeeks of stabilizationHydrochloride therapyOpioid withdrawalBuprenorphine treatmentNaltrexone treatment
2012
Counseling and Directly Observed Medication for Primary Care Buprenorphine Maintenance
Moore BA, Barry DT, Sullivan LE, O'Connor PG, Cutter CJ, Schottenfeld RS, Fiellin DA. Counseling and Directly Observed Medication for Primary Care Buprenorphine Maintenance. Journal Of Addiction Medicine 2012, 6: 205-211. PMID: 22614936, PMCID: PMC3419276, DOI: 10.1097/adm.0b013e3182596492.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyPhysician managementObserved medicationBaseline characteristicsCBT sessionsOpioid-negative urinesIndividual CBT sessionsBuprenorphine maintenanceOpioid useMedication adherencePatient satisfactionPrimary careImproved outcomesTreatment outcomesSession attendanceNegative urineTreatment groupsGreater abstinenceCounseling intensityDrug useTherapist availabilityMedicationsBuprenorphinePatientsIndependent effectsCost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care
Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care. Journal Of General Internal Medicine 2012, 27: 669-676. PMID: 22215271, PMCID: PMC3358393, DOI: 10.1007/s11606-011-1962-8.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCost of IllnessCost-Benefit AnalysisDecision Support TechniquesDrug Administration ScheduleDrug CombinationsDrug CostsHealth Care CostsHumansLong-Term CareMedication AdherenceNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPrimary Health CareQuality-Adjusted Life YearsSensitivity and SpecificityUnited StatesConceptsQuality-adjusted life yearsBUP/NXProbabilistic sensitivity analysesBup/Stable patientsOpioid dependenceLife weightsStable opioid-dependent patientsIncremental cost-effectiveness ratioOpioid-dependent patientsOpioid-dependent individualsOffice-based settingSocietal cost savingsCost-effectiveness ratioDecision analytic modelBroader health systemBuprenorphine-naloxoneOpioid useCohort studyNaloxone treatmentCare physiciansAdditional researchPrimary carePatient costsHypothetical cohort
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence
2005
Response to hepatitis A vaccine in HIV‐positive patients1
Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV‐positive patients1. Journal Of Viral Hepatitis 2005, 13: 81-86. PMID: 16436125, DOI: 10.1111/j.1365-2893.2005.00658.x.Peer-Reviewed Original ResearchConceptsHepatitis A virusHigher CD4 countsHuman immunodeficiency virusCD4 countHAV vaccineVaccine administrationFemale genderImmune responseMultivariate analysisHepatitis C virus exposureUSPHS/IDSA guidelinesHIV-negative patientsAntiretroviral therapy useChronic liver diseasePredictors of responseLow viral loadIDSA guidelinesVaccination seriesHIV patientsIndependent predictorsTherapy useLiver diseaseOpportunistic infectionsViral loadImmunodeficiency virus